201 related articles for article (PubMed ID: 35675514)
1. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.
Li Y; Yang X; Sun Y; Li Z; Yang W; Ju B; Easton J; Pei D; Cheng C; Lee S; Pui CH; Yu J; Chi H; Yang JJ
Blood; 2022 Sep; 140(13):1507-1521. PubMed ID: 35675514
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
3. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
4. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG;
Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472
[TBL] [Abstract][Full Text] [Related]
7. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
9. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
Kauer J; Märklin M; Pflügler M; Hörner S; Hinterleitner C; Tandler C; Jung G; Salih HR; Heitmann JS
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2759-2771. PubMed ID: 35551463
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib.
Sekimizu M; Yamashita Y; Ueki H; Akita N; Hattori H; Maeda N; Horibe K
Leuk Lymphoma; 2014 Jul; 55(7):1652-3. PubMed ID: 24024475
[No Abstract] [Full Text] [Related]
11. Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Ding YY; Kim H; Madden K; Loftus JP; Chen GM; Allen DH; Zhang R; Xu J; Chen CH; Hu Y; Tasian SK; Tan K
Clin Cancer Res; 2021 Sep; 27(18):5109-5122. PubMed ID: 34210682
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
Front Immunol; 2018; 9():2433. PubMed ID: 30405627
[TBL] [Abstract][Full Text] [Related]
15. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
[No Abstract] [Full Text] [Related]
16. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
17. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
[TBL] [Abstract][Full Text] [Related]
18. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Jabbour E; Haddad FG; Short NJ; Kantarjian H
JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
[TBL] [Abstract][Full Text] [Related]
20. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
Ganguly S; Sasi A; Pushpam D; Bakhshi S
Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
